Osmetech starts clinical trials of warfarin assay:
This article was originally published in Clinica
Molecular diagnostics firm Osmetech has initiated clinical trials of its eSensor 2C9/VKOR test, assessing its use in identifying patients at risk for increased sensitivity to warfarin. Patients' genetic make-up may influence how they respond to the blood thinner. The trials are intended to support the company's 510(k) application for US marketing clearance for the 2C9/VKOR assay together with its eSensor XT-8 instrument. Pasadena, California-based Osmetech said that it expects to gain US approval and launch the genetic test in the first half of 2008. eSensor, and electrochemistry-based array system, is already launched in the US for cystic fibrosis carrier detection.
You may also be interested in...
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.